Bayer: Science For A Better Life

United States of America

Alt tag Alt tag

Call For Grants

close print

I. Background

Bayer Pharmaceuticals’ Medical Education department is committed to funding independent medical education initiatives that help to address important healthcare professional educational gaps and improve patient care.

 

II. General Information and Requirements

CGA Issue Date:June 16, 2025
CGA Due Date:July 14, 2025
Initiation of Program Development:September 27, 2025
Areas of Interest based on Referenced Literature:
  • Radiopharmaceuticals in mCRPC
  • Types of Radiopharmaceuticals & practical/clinical considerations
  • Sequencing and combination use with other therapies o Review of clinical data and real-world evidence
  • Shared decision making between HCP & patient  
Type of Initiative:Satellite Symposium at ASTRO + online enduring
Activity Format Examples:Live program with enduring materials/learner-centered, active-learning/Evidence-based learning & improvement programs preferred
Primary Target Audience:Primary Target Audience: Radiation Oncologists, Nuclear Medicine Physicians, Medical Oncologists
Geographic Scope:United States
Expected Monetary Range:Expected Monetary Range: Up to $300,000 – sole sponsorship and/or multi-support sponsorships
How to Submit:

1. Review Bayer Pharmaceuticals Grant Guidelines:

https://www.grants-contributions.bayer.com/home/medical-educational-grants

2. Review additional CGA requirements outlined within this document

3. Submit via Bayer Pharmaceuticals’ online request form:

https://www.grants-contributions.bayer.com/home/medical-educational-grants

NOTE: Please reference ‘Prostate CGA’ in the title

Questions: 

Questions may be submitted to medicaleducation@bayer.com

(please reference ‘Prostate CGA’)

Notification Process: Upon Grant Review Committee evaluation and assessment, the requestor is notified of the decision via e-mail to the address entered on the Grant Request Form

 

III. Proposal Requirements

 

  1. Formal letter of request, including:

     

    1. Program title
    2. Brief Program Outline/description
    3. Program development start date
    4. Target release date of program (if applicable)
    5. Rationale and approach to program placement (if applicable)
    6. Anticipated attendance and breakdown by specialty (if applicable)
    7. Amount requested
    8. CME credits offered
    9. Sponsorship structure/rationale (multi-sponsored preferred but will consider sole sponsorship).
  2. Needs Assessment
  3. Learning Objectives and Educational Gaps: specific, measurable, performance based.
  4. Target Audience and Audience Generation: describe the target audience(s) and provide a rationale for how and why this target audience is important to closing the identified healthcare gap. Additionally, describe methods of reaching the target audience(s) including description and rationale for recruitment strategies.
  5. Educational Method and Design: considers appropriate target audience and learning preferences.
  6. Venue (if applicable): describe target venue (i.e., distribution amongst academic institutions, large community hospitals and networks, restaurants, and others).
  7. Meeting Placement Strategy and Institution Vetting Process (if applicable)
  8. Delivery Format: describe rationale of delivery format.
  9. Potential Faculty
  10. Faculty Recruitment and Training Strategy
  11. Program Development Timeline
  12. Program Agenda
  13. Program Budget: detailed budget with rationale including breakdown of costs with clear calculations.
  14. Educational Outcomes: provide a description of the approach to evaluate the reach and quality of program delivery (minimum outcomes: Moore’s levels 1-4).
  15. Communication/Activity Update Plan (optional)

  16. Completed, recent W-9 form

     

IV. Compliance: grant application must be compliant with ACCME guidelines, free of commercial bias/influence, non-promotional, and fair balanced.

 

V. Terms and Conditions

 

  1. This CGA does not commit Bayer Pharmaceuticals to award a grant or to pay any costs incurred in the preparation of this request.
  2. Bayer Pharmaceuticals reserves the right to accept or reject any or all applications received as a result of this request or to cancel in part or in its entirety this CGA at any time without prior notification or permission.
  3. The grant application must be submitted via Bayer Pharmaceuticals’ online request form: https://www.grants-contributions.bayer.com/home/medical-educational-grants.

  4. All communications about the CGA must come exclusively to Bayer Pharmaceuticals Medical Education, medicaleducation@bayer.com. 

     

VI: Acceptance of a BHC educational grant indicates that you will:

 

  1. Reconcile grant funding within 60 days of completion of the educational program.
  2. Permit a BHC Medical Affairs representative to audit live programs.
  3. Share activity data and outcomes metrics within 30 days of their availability.

 

Literature/Data References:

 

Radiopharmaceuticals in mCRPC 

 

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2025. Published May 10, 2025. Accessed June 17, 2025. https://www.nccn.org 

  2. Bryce AH, Agarwal N, Beltran H, et al. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025;131(1):e35612. doi:10.1002/cncr.35612 https://pubmed.ncbi.nlm.nih.gov/39616467/

  3. Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer: A Review. JAMA. 2025;333(16):1433-1446. doi:10.1001/jama.2025.0228 

  4. Ramnaraign B, Sartor O. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. Oncologist. 2023;28(5):392-401. doi:10.1093/oncolo/oyac279 https://pubmed.ncbi.nlm.nih.gov/36806966/

  5.   Roy, S et al. Use of Radium223 in advanced Prostate Cancer. Reviews in Urology. 2024;24(1). Accessed June 18, 2025. https://articles-cdn.specialtynetworks.com/articles/24_1/Ra-223 for Prostate Cancer_Spratt.pdf

  6. Turco F, Gillessen S, Herrmann K, Paone G, Omlin A. Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy. J Nucl Med. 2025;66(5):665-672. Published 2025 May 1. doi:10.2967/jnumed.124.267730 https://pubmed.ncbi.nlm.nih.gov/40015917/

  7. De Vincentis G, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019 Nov 1;30(11):1728-1739 https://pubmed.ncbi.nlm.nih.gov/31418764/

  8. Taich L, Zhao H, Stock SR, Howard LE, De Hoedt AM, Terris MK, et al. Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice [Internet]. 2022 Sep 1 [cited 2025 Jun 18];9(5):405–13.https://www.auajournals.org/doi/abs/10.1097/UPJ.0000000000000316

  9. Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. Prostate Cancer Prostatic Dis. Published online April 4, 2025. doi:10.1038/s41391-025-00969-6 https://pubmed.ncbi.nlm.nih.gov/40185917/

     

    Types of Radiopharmaceuticals & practical/clinical considerations 

     

  10. Tombal B, Choudhury A, Saad F, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. Ann Oncol. Published online May 30, 2025. doi:10.1016/j.annonc.2025.05.011 https://pubmed.ncbi.nlm.nih.gov/40450503/

  11. Rana R. McKay et al. A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis. JCO 43, 5007-5007(2025). https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5007

  12.  Marshall CH, Fu W, Wang H, et al. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021;27(6):1623-1630. doi:10.1158/1078-0432.CCR-20-4476 https://pubmed.ncbi.nlm.nih.gov/33451978/

  13. Soon YY, Marschner IC, Schou M, et al. Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024;7(9):e2433863. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.33863 https://pmc.ncbi.nlm.nih.gov/articles/PMC11409154/

  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11409154/Lu HH, Chiu NT, Tsai MH. Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy. Ann Nucl Med. 2024;38(7):508-515. doi:10.1007/s12149-024-01924-6 https://pubmed.ncbi.nlm.nih.gov/38647876/

  15. Sartor, AO et al. Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases. Prostate. 2019 Oct;79(14):1683-1691. https://www.ncbi.nlm.nih.gov/pubmed/31442327

  16. Suominen, MI et al. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 2019 Aug 10;20(16). pii: E3899.https://www.ncbi.nlm.nih.gov/pubmed/31405099?otool=idesaglib

  17. Sartor AO., et al. A Retrospective analysis of Treatment Patterns in Metastatic Castration Resistant Prostate Cancer Patients Treated with Radium-223. J Clin Oncol 37, 2019 (suppl 7S, 180). https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.180

  18. Smith M., et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419 https://www.ncbi.nlm.nih.gov/pubmed/30738780

  19. Parker, C.; Sartor, O. Radium-223 in prostate cancer. N. Engl. J. Med. 2013, 369, 1659–1660. https://pubmed.ncbi.nlm.nih.gov/23863050/

     

    Sequencing and combination use with other therapies (Review of clinical data and real-world evidence) 

     

  20. Giacometti V, Grey AC, McCann AJ, et al. An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223. Br J Radiol. 2024;97(1156):794-802. doi:10.1093/bjr/tqae005 https://pubmed.ncbi.nlm.nih.gov/38268482/

  21. Zhou B, Raval AD, Zhang Y, et al. Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study. Clin Genitourin Cancer. Published online May 8, 2025. doi:10.1016/j.clgc.2025.102372 https://pubmed.ncbi.nlm.nih.gov/40450449/

  22. George DS, et al. Clinical outcomes with concurrent or layered treatment with radium-223 and abiraterone plus prednisone/prednisolone: a retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37, 2019 (suppl 7S, 253-253). https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.253

  23. George DS, et al. Clinical outcomes with concurrent or layered treatment with radium-223 and abiraterone plus prednisone/prednisolone: a retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37, 2019 (suppl 7S, 253-253). https://pubmed.ncbi.nlm.nih.gov/34168015/

  24. Rahbar K, Essler M, Eiber M, et al. 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study). J Nucl Med. 2023;64(12):1925-1931. Published 2023 Dec 1. doi:10.2967/jnumed.123.266125 https://pmc.ncbi.nlm.nih.gov/articles/PMC10690117/

  25. Khalaf D, et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy. J Clin Oncol 36, 2018 (suppl; abstr 5015) https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.5015

  26. Sartor AO, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 Jul;76(10):905-16. https://www.ncbi.nlm.nih.gov/pubmed/27004570

  27. Saad F, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016 Sep;17(9):1306-16. https://www.ncbi.nlm.nih.gov/pubmed/?term=Radium-223+and+concomitant+therapies+in+patients+with+metastatic+castration-resistant+prostate+cancer:+an+international,+early+access,+open-label,+single-arm+phase+3b+trial

     

    Shared decision making between HCP & patient

     

  28. Kaye DR, Tu K, Davis JK, et al. Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study. JU Open Plus. 2024;2(3):e00014. doi:10.1097/ju9.0000000000000118 https://pubmed.ncbi.nlm.nih.gov/39281710/

  29. Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. Oncologist. 2023;28(3):246-251. doi:10.1093/oncolo/oyac245 https://pubmed.ncbi.nlm.nih.gov/36651837/

  30. Louhanepessy RD, et al. Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry); a prospective observational registry in a non-study population. Ann. Onc., V29 (suppl_8, Oct 2018, 829P). https://academic.oup.com/annonc/article/29/suppl_8/mdy284.038/5141350

  31. Dizdarevic S. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC Population for long-term Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1102-1110 https://www.ncbi.nlm.nih.gov/pubmed/30637501

  32. Uemura H, Matsubara N, Kimura G, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment [published correction appears in BMC Urol. 2017 Mar 28;17(1):20. doi: 10.1186/s12894-017-0210-x.]. BMC Urol. 2016;16(1):63. Published 2016 Nov 4. doi:10.1186/s12894-016-0182-2 https://pmc.ncbi.nlm.nih.gov/articles/PMC5095997/

  33. Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective. Urology. 2015;85(4):717-724. doi:10.1016/j.urology.2014.11.031 https://pubmed.ncbi.nlm.nih.gov/25681834/

     

    Bone Health

     

  34. Palmedo H, Ahmadzadehfar H, Eschmann S, et al. Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study. J Nucl Med. 2023;64(9):1392-1398. doi:10.2967/jnumed.123.265557

  35. Hanbo Zhang et al.Survival and fracture risk with radium-223 therapy in metastatic castrate-resistant prostate cancer (mCRPC): A real-world analysis.. JCO 42, 50-50(2024).DOI:10.1200/JCO.2024.42.4_suppl.50 https://doi.org/10.1200/JCO.2024.42.4_suppl.50

  36. Gillessen S, et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. Eur Urol. 2019 Jun;75(6):894-895 https://meetinglibrary.asco.org/record/196744/abstract

  37. Tombal BF, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. J Clin Oncol 37, 2019 (suppl 15S; abstr 5007). https://meetinglibrary.asco.org/record/172905/abstract

  38. Poeppel TD, et al. Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-interventional study. Eur Urol Suppl 2019; 18(1); e1210 https://www.sciencedirect.com/science/article/pii/S1569905619308693?via=ihub

  39. Sternberg CN, et al. Use of Bone Health Agents in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223 After Abiraterone: an Interim Review of REASSURE. Ann. Onc., V29 (suppl_8, Oct 2018, 826P). https://www.annalsofoncology.org/article/S0923-7534(19)49356-3/fulltext 

Button

© 2024 Bayer AG

This website contains information on BRAND which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK.

Last update: 26/06/2025

Button